Prabhudas Lilladher Recommends Buy on Torrent Pharmaceuticals with Rs 5,500 Target
Prabhudas Lilladher maintains a 'BUY' rating on Torrent Pharmaceuticals with a revised target price of Rs 5,500 per share, based on a 25x EV/EBITDA valuation for September 2028. The company reported a 20% year-on-year growth in base business EBITDA for Q2 FY27, driven by strong domestic performance and resolution of supply disruptions in injectable semaglutide. Integration of JB Chemicals & Pharma is ahead of schedule, delivering cost synergies exceeding initial estimates and expected revenue synergies from FY28, enhancing Torrent's market position and portfolio diversification.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 30/100.
Outlets measured: moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 26 Oct, 07:17 am. Other outlets followed.
- 1